Last reviewed · How we verify
Intraperitoneal infiltration to liver — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intraperitoneal infiltration to liver (Intraperitoneal infiltration to liver) — Royal College of Surgeons, Ireland.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intraperitoneal infiltration to liver TARGET | Intraperitoneal infiltration to liver | Royal College of Surgeons, Ireland | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intraperitoneal infiltration to liver CI watch — RSS
- Intraperitoneal infiltration to liver CI watch — Atom
- Intraperitoneal infiltration to liver CI watch — JSON
- Intraperitoneal infiltration to liver alone — RSS
Cite this brief
Drug Landscape (2026). Intraperitoneal infiltration to liver — Competitive Intelligence Brief. https://druglandscape.com/ci/intraperitoneal-infiltration-to-liver. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab